𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: a systematic review

✍ Scribed by Malcolm Steiger; W. Jost; F. Grandas; G. Van Camp


Publisher
Springer
Year
2009
Tongue
English
Weight
238 KB
Volume
116
Category
Article
ISSN
1435-1463

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


The risk of valvular regurgitation in pa
✍ Vibeke Guldbrand Rasmussen; Karen Østergaard; Erik Dupont; Steen Hvitfeldt Pouls 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB 👁 1 views

## Abstract ## Objectives: Several observational studies suggest an association between treatment with ergoline‐derived dopamine agonists and valvular regurgitation. In this article, we present an overview of the literature and conduct a meta‐analysis. ## Methods: Observational studies addressin

Valvular heart disease in Parkinson's di
✍ Susann Junghanns; Joerg T. Fuhrmann; Gregor Simonis; Christian Oelwein; Rainer K 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

## Abstract Fibrotic valvular heart disease (VHD) has been reported in association with ergot dopamine agonists (DAs), but the current database is insufficient regarding clinical relevance and comparison to data on non‐ergot DAs. We evaluated the effects of four DAs (pergolide, cabergoline, ropinir

Meta-analysis of heart valve abnormaliti
✍ Gregor Simonis; Joerg T. Fuhrmann; Ruth H. Strasser 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 1 views

## Abstract Valvular heart disease in patients being treated with ergot‐derivative dopamine agonists (Ergot‐DA) for Parkinson's disease has been reported to occur as a consequence of serotonine receptor stimulation. Goal of this analysis was to estimate the incidence of those changes from recently